Annual report pursuant to Section 13 and 15(d)

Schedule II - Valuation and Qualifying Accounts

v3.24.0.1
Schedule II - Valuation and Qualifying Accounts
 12 Months Ended
Dec. 30, 2023
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation And Qualifying Accounts
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
(in thousands)
Description Balance at beginning of period Charged to costs and expenses Deductions Balance at end of period
December 30, 2023
Allowance for sales returns $ 572  $ 5,552  $ 5,704  $ 420 
Allowance for credit losses $ 363  $ 112  $ 54  $ 421 
Valuation allowance - deferred tax assets $ 118,136  $ 19,116  $ —  $ 137,252 
December 31, 2022
Allowance for sales returns $ 547  $ 6,562  $ 6,537  $ 572 
Allowance for credit losses $ 504  $ 6  $ 147  $ 363 
Valuation allowance - deferred tax assets $ 99,958  $ 18,178  $ —  $ 118,136 
January 1, 2022
Allowance for sales returns $ 819  $ 7,213  $ 7,485  $ 547 
Allowance for credit losses $ 372  $ 148  $ 16  $ 504 
Valuation allowance - deferred tax assets $ 81,401  $ 18,557  $ —  $ 99,958